Effectiveness of tyrosine kinase inhibitors on uncommon E709X epidermal growth factor receptor mutations in non-small-cell lung cancer
Open accessAbstract
Background: Clinical features of epidermal growth factor receptor (EGFR) mutations: L858R, deletions in exon 19, T790M, insertions in exon 20, G719X, and L861X in non-small-cell lung cancer (NSCLC) are well-known. The clinical significance of other uncommon EGFR mutations, such as E709X, is not well understood. This study aimed to improve the understanding of E709X, and the clinical response to tyrosine kinase inhibitors (TKIs) of NSCLC patients with such an uncommon mutation. Methods: Specimens from 3,146 patients were tested for EGFR mutations. We surveyed the clinical data and the effectiveness of TKI treatment in NSCLC patients with EGFR mutations E709X. Results: Of the 3,146 patients, 1,689 (53.7%) had EGFR mutations. This included 726 patients with deletions in exon 19, 733 patients with L858R, and 230 (13.6%) patients with other EGFR mutations. In the 230 patients who had mutations other than single deletion in exon 19 or single L858R in exon 21, 25 (1.5%) patients had the uncommon E709X mutations. Twenty patients had complex E709X mutations and five had single E709X mutation: delE709-T710insD. Of these 25 patients, 18 received either gefitinib or erlotinib treatment. The response rate of TKIs treatment was 50.0%, and the median progression-free survival was 6.2 months. All 5 patients who had delE709-T710insD were non-responders to TKI treatments. Conclusion: E709X EGFR mutations constituted a small part of the whole group of EGFR mutations. Most patients had complex mutations. The mutation delE709-T710insD was a single mutation and was not associated with good response to TKI treatment. Keywords: EGFR, erlotinib, gefitinib, lung cancer, mutations
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Increasing evidence suggests a better outcome among patients harboring complex exon 18 mutations compared with those with single EGFR exon 18 mutations.
“increasing evidence suggests a better outcome among patients harboring complex exon 18 mutations, compared with those with single EGFR exon 18 mutations [19,41,50].”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660 · see citing works
<i>EGFR</i> Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368 · see citing works
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
Mok, T. S., Wu, Y.-L., Thongprasert, S., Yang, C.-H., Chu, D.-T., Saijo, N., Sunpaweravong, P., Han, B., Margono, B., Ichinose, Y., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810699 · Cited by 8,261 · see citing works
Pao, W., Miller, V. A., Politi, K. A., Riely, G. J., Somwar, R., Zakowski, M. F., Kris, M. G., & Varmus, H. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020073 · Cited by 3,527 · cited 3× · see citing works
“In conclusion, we reported on a large group of lung cancer patients with uncommon EGFR E709X mutations and their association with treatment of EGFR TKIs.”
Epidermal growth factor receptor mutations in lung cancer
Sharma, S. V., Bell, D. W., Settleman, J., & Haber, D. A. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2088 · Cited by 3,170 · see citing works
Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer
Rosell, R., Moran, T., Queralt, C., Porta, R., Cardenal, F., Camps, C., Majem, M., Lopez-Vivanco, G., Isla, D., Provencio, M., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0904554 · Cited by 2,373 · see citing works
Pathology and genetics of tumours of the lung , pleura, thymus and heart
Travis, W. D. (2004) · Cited by 1,970 · see citing works
Erlotinib in Lung Cancer — Molecular and Clinical Predictors of Outcome
Tsao, M., Sakurada, A., Cutz, J.-C., Zhu, C., Kamel‐Reid, S., Squire, J. A., Lorimer, I. A. J., Zhang, T., Liu, G., Daneshmand, M., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050736 · Cited by 1,815 · see citing works
Detection of Mutations in <i>EGFR</i> in Circulating Lung-Cancer Cells
Maheswaran, S., Sequist, L. V., Nagrath, S., Ulkus, L., Brannigan, B., Collura, C. V., Inserra, E., Diederichs, S., Iafrate, A. J., Bell, D. W., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0800668 · Cited by 1,617 · see citing works
Mitsudomi, T., Kosaka, T., Endoh, H., Horio, Y., Hida, T., Mori, S., Hatooka, S., Shinoda, M., Takahashi, T., & Yatabe, Y. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.00.992 · Cited by 938 · see citing works
Balak, M. N., Gong, Y., Riely, G. J., Somwar, R., Li, A. R., Zakowski, M. F., Chiang, A. C., Yang, G., Ouerfelli, O., Kris, M. G., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1570 · Cited by 823 · see citing works
EGFR Mutations in Lung Cancer: Correlation With Clinical Response to Gefitinib Therapy
Tanoue, L. T. (2006) · Yearbook of Pulmonary Disease · doi:10.1016/s8756-3452(08)70092-6 · Cited by 768 · see citing works
Han, S., Kim, T., Hwang, P. G., Jeong, S., Kim, J., Choi, I. S., Oh, D., Kim, J. H., Kim, D., Chung, D. H., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.388 · Cited by 757 · see citing works
Hirsch, F. R., Varella-Garcia, M., Bunn, P. A., Franklin, W. A., Dziadziuszko, R., Thatcher, N., Chang, A., Parikh, P., Pereira, J. R., Ciuleanu, T., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.3958 · Cited by 703 · see citing works
Oncogenic Transformation by Inhibitor-Sensitive and -Resistant EGFR Mutants
Greulich, H., Chen, T.-H., Feng, W., Jänne, P. A., Alvarez, J. V., Zappaterra, M., Bulmer, S. E., Frank, D. A., Hahn, W. C., Sellers, W. R., et al. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020313 · Cited by 677 · see citing works
New guidelines to evaluate the response to treatment in solid tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Glabbeke, M. M. V., van Oosterom, A. T., Christian, M. C., et al. (2005) · Breast Cancer · doi:10.1007/bf02967383 · Cited by 662 · see citing works
Wu, J.-Y., Yu, C.-J., Chang, Y.-C., Yang, C.-H., Shih, J.-Y., & Yang, P.-C. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-3408 · Cited by 463 · see citing works
Self-citationBeau-Faller, M., Prim, N., Ruppert, A.-M., Nanni-Metéllus, I., Lacave, R., Lacroix, L., Escande, F., Lizard, S., Pretet, J.-L., Rouquette, I., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdt418 · Cited by 324 · see citing works
Wu, J.-Y., Wu, S.-G., Yang, C.-H., Gow, C.-H., Chang, Y.-L., Yu, C.-J., Shih, J.-Y., & Yang, P.-C. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-5123 · Cited by 319 · see citing works
Self-citationRosell, R., Molina, M. A., Costa, C., Simonetti, S., Gimenez-Capitan, A., Bertran-Alamillo, J., Mayo, C., Moran, T., Mendez, P., Cardenal, F., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2158 · Cited by 304 · see citing works
Yang, C.-H., Yu, C., Shih, J., Chang, Y., Hu, F., Tsai, M.-C., Chen, K., Lin, Z., Huang, C.-J., Shun, C., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.6695 · Cited by 235 · see citing works
Self-citationCompound EGFR Mutations and Response to EGFR Tyrosine Kinase Inhibitors
Kobayashi, S., Canepa, H. M., Bailey, A. S., Nakayama, S., Yamaguchi, N., Goldstein, M. A., Huberman, M. S., & Costa, D. B. (2013) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3182781e35 · Cited by 213 · see citing works
Epidermal Growth Factor Receptor Mutations in Small Cell Lung Cancer
Tatematsu, A., Shimizu, J., Murakami, Y., Horio, Y., Nakamura, S., Hida, T., Mitsudomi, T., & Yatabe, Y. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0332 · Cited by 191 · see citing works
Lara, P. N., Redman, M. W., Kelly, K. L., Edelman, M. J., Williamson, S. K., Crowley, J. J., & Gandara, D. R. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.0344 · Cited by 182 · see citing works
Shih, J., Gow, C., Yu, C., Yang, C., Chang, Y., Tsai, M., Hsu, Y., Chen, K., Su, W., & Yang, P. (2005) · International Journal of Cancer · doi:10.1002/ijc.21458 · Cited by 170 · see citing works
Self-citationMutations of the epidermal growth factor receptor in non-small cell lung cancer – Search and destroy
Chan, S. K., Gullick, W. J., & Hill, M. E. (2005) · European Journal of Cancer · doi:10.1016/j.ejca.2005.07.031 · Cited by 165 · see citing works
De Pas, T., Toffalorio, F., Manzotti, M., Fumagalli, C., Spitaleri, G., Catania, C., Delmonte, A., Giovannini, M., Spaggiari, L., de Braud, F., et al. (2011) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318227e8c6 · Cited by 138 · see citing works
Detection of Mutations in EGFR in Circulating Lung-Cancer Cells
Tanoue, L. T. (2010) · Yearbook of Pulmonary Disease · doi:10.1016/s8756-3452(09)79360-0 · Cited by 137 · see citing works
Wu, S.-G., Gow, C.-H., Yu, C., Chang, Y., Yang, J. C., Hsu, Y., Shih, J.-Y., Lee, Y.-C., & Yang, P. (2008) · European Respiratory Journal · doi:10.1183/09031936.00167407 · Cited by 127 · see citing works
Self-citationKeam, B., Kim, D.-W., Park, J. H., Lee, J.-O., Kim, T. M., Lee, S.-H., Chung, D. H., & Heo, D. S. (2014) · International Journal of Clinical Oncology · doi:10.1007/s10147-013-0602-1 · Cited by 113 · see citing works
Epidermal Growth Factor Receptor Mutations in Small Cell Lung Cancer: A Brief Report
Shiao, T., Chang, Y., Yu, C., Chang, Y., Hsu, Y.-C., Chang, S.-H., Shih, J., & Yang, P. (2010) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181f94abb · Cited by 94 · see citing works
Self-citationPallis, A. G., Voutsina, A., Kalikaki, A., Souglakos, J., Briasoulis, E. C., Murray, S. J., Koutsopoulos, A. V., Tripaki, M., Stathopoulos, E. N., Mavroudis, D., et al. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6604068 · Cited by 90 · see citing works
Chen, Z., Feng, J., Saldivar, J.-S., Gu, D., Bockholt, A., & Sommer, S. S. (2008) · Oncogene · doi:10.1038/onc.2008.71 · Cited by 81 · see citing works
Wu, S., Chang, Y., Hsu, Y.-C., Wu, J., Yang, C.-H., Yu, C., Tsai, M., Shih, J., & Yang, P. (2008) · The Oncologist · doi:10.1634/theoncologist.2008-0093 · Cited by 77 · see citing works
Self-citationComparison of gefitinib and erlotinib in advanced NSCLC and the effect of EGFR mutations
Wu, J., Wu, S., Yang, C.-H., et al. (2010) · Lung Cancer · doi:10.1016/j.lungcan.2010.08.013 · Cited by 76 · see citing works
Self-citationFirst- or Second-line Therapy with Gefitinib Produces Equal Survival in Non–Small Cell Lung Cancer
Wu, J., Yu, C., Yang, C.-H., Wu, S., Chiu, Y., Gow, C., Chang, Y., Hsu, Y.-C., Wei, P., Shih, J., et al. (2008) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200803-389oc · Cited by 70 · see citing works
Self-citationGu, D., Scaringe, W. A., Li, K., Saldivar, J., Hill, K. A., Chen, Z., Hagman, K. D. F., & Sommer, S. S. (2007) · Human Mutation · doi:10.1002/humu.20512 · Cited by 60 · see citing works
Patterns of DNA Mutations and ALK Rearrangement in Resected Node Negative Lung Adenocarcinoma
Yip, P. Y., Yu, B., Cooper, W. A., Selinger, C. I., Ng, C. C., Kennedy, C. W., Kohonen‐Corish, M. R. J., McCaughan, B. C., Trent, R. J., Boyer, M. J., et al. (2013) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318283558e · Cited by 45 · see citing works
Erlotinib in Lung Cancer — Molecular and Clinical Predictors of Outcome
(2006) · New England Journal of Medicine · doi:10.1056/nejmx060060 · Cited by 41 · see citing works
Cheng, C., Wang, R., Li, Y., Pan, Y., Zhang, Y., Li, H., Zheng, D., Zheng, S., Shen, X., Sun, Y., et al. (2015) · Scientific Reports · doi:10.1038/srep13959 · Cited by 38 · see citing works
Ackerman, A., Goldstein, M. A., Kobayashi, S. S., et al. (2012) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3182635ab4 · Cited by 34 · see citing works
Hijiya, N., Miyawaki, M., Kawahara, K., Akamine, S., Tsuji, K., Kadota, J., Akizuki, S., Uchida, T., Matsuura, K., Tsukamoto, Y., et al. (2008) · Human Pathology · doi:10.1016/j.humpath.2007.10.027 · Cited by 24 · see citing works
Wu, J., Yu, C., Shih, J., et al. (2009) · Lung Cancer · doi:10.1016/j.lungcan.2009.04.018 · Cited by 20 · see citing works
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Russo, A., Franchina, T., Ricciardi, G., Battaglia, A., Picciotto, M., & Adamo, V. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20061431 · Cited by 110 · see citing works
Shen, Y.-C., Tseng, G.-C., Tu, C.-Y., Chen, W.-C., Liao, W.-C., Chen, W.-C., Li, C.-H., Chen, H.-J., & Hsia, T.-C. (2017) · Lung Cancer · doi:10.1016/j.lungcan.2017.06.007 · Cited by 99 · see citing works
- Authors
- Wu, J.-Y., & Shih, J.-Y.
- Affiliations
- National Taiwan University Hospital (TW)
- National Taiwan University (TW)
- Corresponding author
- Shih, Jin-Yuan
- ORCID
- Shih, Jin-Yuan
- Venue
- OncoTargets and Therapy
- Publisher
- Informa UK Limited
- Published
- 2016-10
- Volume
- Volume 9
- Pages
- 6137-6145
- ISSN
- 1178-6930 (ISSN-L)
- PMC
- PMC5067004
- OpenAlex
- W2530772402
- Cited by
- 44
- References
- 43
- Citations by year
- 2026: 1 · 2025: 2 · 2024: 7 · 2023: 3 · 2022: 7 · 2021: 3 · 2020: 2 · 2019: 13 · 2018: 4 · 2017: 2
- FWCI
- 5.66
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- OncoTargets and Therapy (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Dove Medical Press (Taylor and Francis Group) (submittedVersion, cc-by-nc)
- Funders
- National Taiwan University Hospital (104-S2675)
- National Taiwan University (104-S2675)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
- Keywords
- EGFR mutation, non-small cell lung cancer, tyrosine kinase inhibitors, gefitinib, erlotinib, treatment response, exon 20 insertion
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
